Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 5.6% on Monday . The stock traded as low as C$0.09 and last traded at C$0.09. Approximately 11,328 shares were traded during trading, a decline of 42% from the average daily volume of 19,372 shares. The stock had previously closed at C$0.09.
Hemostemix Stock Up 5.9%
The firm has a 50-day moving average price of C$0.09 and a two-hundred day moving average price of C$0.10. The company has a market capitalization of C$16.96 million, a P/E ratio of -3.33 and a beta of 1.25. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Featured Stories
- Five stocks we like better than Hemostemix
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- You Still Think Silver’s a Joke? Watch What Happens Next.
- This stock gets a 94 out of 100
- Punch these codes into your ordinary brokerage account
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
